What are pharmacological chaperones and why are they interesting?

Journal of Biology

Volumn 8, Issue 9, 2009, Pages

  Ringe, Dagmar ^a   Petsko, Gregory A ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE;

ALZHEIMER DISEASE; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; CYSTIC FIBROSIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; RADIATION EXPOSURE;

ENZYME ACTIVATION; HUMANS; MOLECULAR CHAPERONES; PROTEIN BINDING; PROTEIN FOLDING;

EID: 70350347721     PISSN: None     EISSN: 14754924     Source Type: Journal    
DOI: 10.1186/jbiol186     Document Type: Note

References (27)

1. Converging concepts of protein folding in vitro and in vivo. FU Hartl M Hayer-Hartl, Nat Struct Mol Biol 2009 16 574 581 10.1038/nsmb.1591 19491934
2. Macromolecular crowding: an important but neglected aspect of the intracellular environment. RJ Ellis, Curr Opin Struct Biol 2001 11 114 119 10.1016/S0959-440X(00)00172-X 11179900
3. DS Goodsell, The Machinery of Life New York: Springer-Verlag 1992
4. Protein misfolding in conformational disorders: rescue of folding defects and chemical chaperoning. P Leandro CM Gomes, Mini Rev Med Chem 2008 8 901 911 10.2174/138955708785132783 18691147
5. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. T Arakawa D Ejima Y Kita K Tsumoto, Biochim Biophys Acta 2006 1764 1677 1687 17046342
6. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. A Ulloa-Aguirre JA Janovick SP Brothers PM Conn, Traffic 2004 5 821 837 10.1111/j.1600-0854.2004.00232.x 15479448
7. From structure to function. GA Petsko D Ringe, Protein Structure and Function London; New Science Press 2004 56 60
8. Protein-misfolding diseases and chaperone-based therapeutic approaches. TK Chaudhuri S Paul, FEBS J 2006 273 1331 1349 10.1111/j.1742-4658.2006.05181.x 16689923
9. Chemical and pharmacological chaperones as new therapeutic agents. TW Loo DM Clarke, Expert Rev Mol Med 2007 9 1 18 10.1017/S1462399407000361 17597553
10. Therapeutic strategies to ameliorate lysosomal storage disorders - a focus on Gaucher disease. AR Sawkar W D'Haeze JW Kelly, Cell Mol Life Sci 2006 63 1179 1192 10.1007/s00018-005-5437-0 16568247
11. Ligand effects on protein thermodynamic stability. JM Sanchez-Ruiz, Biophys Chem 2007 126 43 49 10.1016/j.bpc.2006.05.021 16781051
12. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. JQ Fan, Biol Chem 2008 389 1 11 10.1515/BC.2008.009 18095864
13. What makes a binding site a binding site? D Ringe, Curr Opin Struct Biol 1995 5 825 829 10.1016/0959-440X(95)80017-4 8749372
14. Multiple solvent crystal structures: probing binding sites, plasticity and hydration. C Mattos CR Bellamacina E Peisach A Pereira D Vitkup GA Petsko D Ringe, J Mol Biol 2006 357 1471 1482 10.1016/j.jmb.2006.01.039 16488429
15. Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase. MR Landon RL Lieberman QQ Hoang S Ju JM Caaveiro SD Orwig D Kozakov R Brenke GY Chuang D Beglov S Vajda GA Petsko D Ringe, J Comput Aided Mol Des 2009 [Epub ahead of print] 19521672 10.1007/s10822-009-9283-2
16. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. AL Pey B Pérez LR Desviat MA Martínez C Aguado H Erlandsen A Gmez RC Stevens M Thárálfsson M Ugarte A Martínez, Hum Mutat 2004 24 388 399 10.1002/humu.20097 15459954
17. Therapy through chaperones: sense or anti-sense? Cystic fibrosis as a model disease. MD Amaral, J Inherit Metab Dis 2006 29 477 487 10.1007/s10545-006-0251-x 16763920
18. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. U Ozcan E Yilmaz L Ozcan M Furuhashi E Vaillancourt RO Smith CZ Görgün GS Hotamisligil, Science 2006 313 1137 1140 10.1126/science.1128294 16931765
19. Therapeutic approaches to protein-misfolding diseases. FE Cohen JW Kelly, Nature 2003 426 905 909 10.1038/nature02265 14685252
20. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. SM Johnson RL Wiseman Y Sekijima NS Green SL Adamski-Werner JW Kelly, Acc Chem Res 2005 38 911 921 10.1021/ar020073i 16359163
21. Correlation of clinical outcomes and disease burden in patients with transthyretin (TTR) amyloid polyneuropathy: study Fx-005, a landmark clinical trail of Fx-1006A, a novel small molecule TTR stabilizer. T Coelho M Waddington-Cruz V Planté-Bordeneuve D Cros D Roy Grogan J Packman, J Neurol 2008 255 Suppl 2 78
22. A landmark clinical trial of a novel small molecule transthyretin (TTR) stabilizer, Fx-1006A, in patients with TTR amyloid polyneuropathy: a phase II/III, randomized, double-blind, placebo-controlled study. M Waddington-Cruz T Coelho L Maia A Martins da Silva V Planté-Bordeneuve O Suhr J Campistol I Conceiçao H Schmidt P Trigo D Cros D Roy Grogan J Packman, J Neurol 2008 255 Suppl 2 107
23. Treatment perspectives for the lysosomal storage diseases. GA Grabowski, Expert Opin Emerg Drugs 2008 13 197 211 10.1517/14728214.13.1.197 18321157
24. The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. RA Steet S Chung B Wustman A Powe H Do SA Kornfeld, Proc Natl Acad Sci USA 2006 103 13813 13818 16945909 10.1073/pnas.0605928103 (Pubitemid 44413990)
25. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. RL Lieberman BA Wustman P Huertas AC Powe Jr CW Pine R Khanna MG Schlossmacher D Ringe GA Petsko, Nat Chem Biol 2007 3 101 107 10.1038/nchembio850 17187079
26. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. JQ Fan S Ishii, FEBS J 2007 274 4962 4971 10.1111/j.1742-4658.2007.06041.x 17894781
27. A role for protein misfolding in immunogenicity of biopharmaceuticals. C Maas S Hermeling B Bouma W Jiskoot MF Gebbink, J Biol Chem 2007 282 2229 2236 10.1074/jbc.M605984200 17135263